AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26864131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 25077910 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal thoracic interbody fusion (TTIF)
Number of subjects: 61
Study 25077910 — intervention group
Group type: COMPARATOR
Intervention: Posteroanterior (P-A) fusion
Number of subjects: 61
Study 22391540 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline (TMC207)
Number of subjects: 47
Study 22391540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19619101 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention for general practitioners
Number of subjects: 107
Study 19619101 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 107
Study 17617892 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery after PPROM
Number of subjects: 520
Study 17617892 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 520
Study 15116254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) thromboprophylaxis
Number of subjects: 61
Study 15116254 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy pregnant women without antithrombotics)
Number of subjects: 61
Study 11668032 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.25, 0.75, or 1.5 mg)
Number of subjects: 30
Study 11668032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol (2.5, 5, or 10 mg)
Number of subjects: 30
Study 11668032 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 9690105 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy in discussing mammography with health providers
Number of subjects: 194
Study 9690105 — intervention group
Group type: EXPERIMENTAL
Intervention: Social influence from network members regarding mammograms
Number of subjects: 194
Study 7977327 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg orally)
Number of subjects: 20
Study 7977327 — intervention group
Group type: COMPARATOR
Intervention: Conversion from CsA to azathioprine
Number of subjects: 20
Study 2686610 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime (+/‐ flucloxacillin) (n = 52)
Number of subjects: 102
Study 2686610 — intervention group
Group type: COMPARATOR
Intervention: azlocillin plus amikacin (+/‐ flucloxacillin) (A&A, n = 50)
Number of subjects: 102
Study 2686610 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime (+/‐ flucloxacillin)
Number of subjects: 102
Study 2686610 — intervention group
Group type: COMPARATOR
Intervention: azlocillin plus amikacin (+/‐ flucloxacillin)
Number of subjects: 102
Study 818818 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (GCL)
Number of subjects: 50
Study 29668561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide plus lactulose
Number of subjects: 120
Study 29668561 — intervention group
Group type: COMPARATOR
Intervention: Lactulose and placebo
Number of subjects: 120
Study 28763881 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine combined Reinhartdt And Sea Cucumber Capsule (R.S.C)
Number of subjects: 158
Study 28763881 — intervention group
Group type: COMPARATOR
Intervention: Single Memantine
Number of subjects: 158
Study 25619686 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe cream
Number of subjects: 248
Study 25619686 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 248
Study 25619686 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder
Number of subjects: 248
Study 23771550 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 17
Study 23771550 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 17
Study 23771550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 21644312 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with general anesthesia (ACGA)
Number of subjects: 39
Study 21644312 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 39
Study 18840368 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (5 mg, oral)
Number of subjects: 15
Study 18840368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17065942 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with HCP
Number of subjects: 42
Study 17065942 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 42
Study 12580653 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of HMB per day for 4 weeks
Number of subjects: 35
Study 12580653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10831205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (1.0 mg for age > 60 yr; 1.5 mg for age ≤ 59 yr)
Number of subjects: 25
Study 10831205 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized anesthetic with fentanyl, propofol, and pancuronium)
Number of subjects: 25
Study 9106275 — intervention group
Group type: EXPERIMENTAL
Intervention: Original and reversed (mirror-image) viewing conditions in Experiment 1
Number of subjects: 0
Study 9106275 — intervention group
Group type: EXPERIMENTAL
Intervention: Original and reversed (mirror-image) viewing conditions in Experiment 2
Number of subjects: 0
Study 8476829 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial resection
Number of subjects: 200
Study 8476829 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 200
Study 2428219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiacrilast (Ro 22-3747) 350 mg oral dose
Number of subjects: 0
Study 2428219 — intervention group
Group type: COMPARATOR
Intervention: Cromoglycate 20 mg by inhalation
Number of subjects: 0
Study 2428219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29608460 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 28
Study 29608460 — intervention group
Group type: COMPARATOR
Intervention: Parental Training (PT)
Number of subjects: 28
Study 29608460 — intervention group
Group type: COMPARATOR
Intervention: Parental Training/Methylphenidate (PT/MPH)
Number of subjects: 28
Study 27861516 — intervention group
Group type: EXPERIMENTAL
Intervention: mCME intervention - Group 2 (passive model): daily SMS bullet point, required to reply to acknowledge receipt
Number of subjects: 638
Study 27861516 — intervention group
Group type: EXPERIMENTAL
Intervention: mCME intervention - Group 3 (interactive model): SMS in multiple choice question format with immediate feedback
Number of subjects: 638
Study 27861516 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 638
Study 27861516 — intervention group
Group type: EXPERIMENTAL
Intervention: mCME intervention (both Groups 2 and 3)
Number of subjects: 638
Study 24508367 — intervention group
Group type: EXPERIMENTAL
Intervention: short-term psychotherapy (short-term psychodynamic or solution-focused)
Number of subjects: 326
Study 24508367 — intervention group
Group type: EXPERIMENTAL
Intervention: long-term psychodynamic psychotherapy
Number of subjects: 326
Study 24508367 — intervention group
Group type: COMPARATOR
Intervention: low level of social support
Number of subjects: 326
Study 22642356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal to down‐regulate responses
Number of subjects: 0
Study 22642356 — intervention group
Group type: EXPERIMENTAL
Intervention: Different reappraisal task
Number of subjects: 0
Study 19810668 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated clinical experiences
Number of subjects: 74
Study 19810668 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical experiences
Number of subjects: 74
Study 18591525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (2 mL of a 24% sucrose solution)
Number of subjects: 240
Study 18591525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 15741556 — intervention group
Group type: EXPERIMENTAL
Intervention: ARILVAX
Number of subjects: 1107
Study 15741556 — intervention group
Group type: COMPARATOR
Intervention: YF-VAX
Number of subjects: 1107
Study 12939564 — intervention group
Group type: EXPERIMENTAL
Intervention: lercanidipine 10 mg
Number of subjects: 250
Study 12939564 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine 10 mg
Number of subjects: 250
Study 12939564 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine gastrointestinal therapeutic system 30 mg
Number of subjects: 250
Study 12939564 — intervention group
Group type: COMPARATOR
Intervention: All groups (lercanidipine, felodipine, nifedipine)
Number of subjects: 250
Study 10788737 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week health promotion intervention
Number of subjects: 35
Study 8869092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 6 mg/m2 administered 1-2 hours before each radiation fraction, with escalating total doses during treatment.
Number of subjects: 38
Study 1531095 — intervention group
Group type: EXPERIMENTAL
Intervention: T10B9.1A‐31
Number of subjects: 38
Study 1531095 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 38
Study 6238116 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118630 (Zoladex) 3.6 mg
Number of subjects: 22
Study 6238116 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118630 (Zoladex) 1.8 mg
Number of subjects: 22
Study 6238116 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118630 (Zoladex) 0.9 mg
Number of subjects: 22
Study 6238116 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118630 (Zoladex) (all doses)
Number of subjects: 22
Study 30860000 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine extended-release oral suspension (AMPH EROS)
Number of subjects: 0
Study 28778126 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 307
Study 28778126 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 307
Study 28778126 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Support
Number of subjects: 307
Study 28778126 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling rested upon waking
Number of subjects: 307
Study 27734492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic nerve catheter between the tibial and peroneal components
Number of subjects: 84
Study 27734492 — intervention group
Group type: COMPARATOR
Intervention: Tibial nerve catheter medial to the tibial nerve
Number of subjects: 84
Study 25339485 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (20 mg/d) treatment group
Number of subjects: 67
Study 25339485 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 67
Study 25339485 — intervention group
Group type: COMPARATOR
Intervention: Control group (sinus rhythm)
Number of subjects: 67
Study 22866821 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (A + D)
Number of subjects: 662
Study 22866821 — intervention group
Group type: COMPARATOR
Intervention: Aspirin only (A)
Number of subjects: 662
Study 19931382 — intervention group
Group type: EXPERIMENTAL
Intervention: 2+1-dose schedule
Number of subjects: 2
Study 19931382 — intervention group
Group type: EXPERIMENTAL
Intervention: 3+1-dose schedule
Number of subjects: 2
Study 17509485 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 1018
Study 17509485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018
Study 15705360 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (50-200 mg/day)
Number of subjects: 14
Study 15705360 — intervention group
Group type: COMPARATOR
Intervention: Lithium (open treatment for a minimum of 4 weeks)
Number of subjects: 14
Study 15705360 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 14
Study 11917239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin-A (CsA) 2 mg/kg twice daily for 12 weeks
Number of subjects: 28
Study 11917239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9457004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered physical activity frequency questionnaire (PAFQ)
Number of subjects: 919
Study 9457004 — intervention group
Group type: COMPARATOR
Intervention: Heart rate monitor
Number of subjects: 919
Study 7606604 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin-coated human cerumen plug placed in one ear
Number of subjects: 43
Study 2220725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension (1 g/10 ml) plus cimetidine (300 mg qid)
Number of subjects: 36
Study 2220725 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (300 mg qid)
Number of subjects: 36
Study 370976 — intervention group
Group type: EXPERIMENTAL
Intervention: Na‐ioxitalamate
Number of subjects: 1628
Study 370976 — intervention group
Group type: COMPARATOR
Intervention: Na‐methylglucamine‐diatrizoate
Number of subjects: 1628
Study 31633789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose venlafaxine (≤150 mg/d)
Number of subjects: 227
Study 31034045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefeed gastric residual evaluation (residual group)
Number of subjects: 143
Study 31034045 — intervention group
Group type: COMPARATOR
Intervention: Omission of gastric residual evaluation (no residual group)
Number of subjects: 143
Study 30079643 — intervention group
Group type: EXPERIMENTAL
Intervention: SC patients
Number of subjects: 98
Study 30079643 — intervention group
Group type: COMPARATOR
Intervention: SS patients
Number of subjects: 98
Study 25707477 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0109‐0012 (3 mg/kg per week, subcutaneously)
Number of subjects: 67
Study 25707477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 23388003 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 10 mg once daily for 35±4 days
Number of subjects: 8101
Study 23388003 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin, 40 mg once daily for 10±4 days followed by placebo
Number of subjects: 8101
Study 21163281 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 3 mg kg(‐1) ingested 60 min before and 45 min after exercise in 33°C
Number of subjects: 11
Study 21163281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) in 33°C
Number of subjects: 11
Study 21163281 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) in 12°C
Number of subjects: 11
Study 21163281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) in 12°C
Number of subjects: 11
Study 19474135 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g low-TFA lipids/d (0.54 g/d; n = 21)
Number of subjects: 63
Study 19474135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminant TFA-rich lipids (4.86 g/d; n = 21)
Number of subjects: 63
Study 19474135 — intervention group
Group type: EXPERIMENTAL
Intervention: Industrial TFA-rich lipids (5.58 g/d; n = 21)
Number of subjects: 63
Study 17190428 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid group
Number of subjects: 30
Study 17190428 — intervention group
Group type: COMPARATOR
Intervention: Contrast group
Number of subjects: 30
Study 15209643 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine at a maintenance dose of 16 or 24 mg/d
Number of subjects: 659
Study 15209643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study 11575284 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of ADL 8‐2698
Number of subjects: 79
Study 11575284 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of ADL 8‐2698
Number of subjects: 79
Study 11575284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 9783800 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa (TTP) 5 mg/kg x 2 days (days -4, -3) along with busulfan (BU) 4 mg/kg x 4 days and cyclophosphamide (CY) 60 mg/kg x 2 days
Number of subjects: 33
Study 9783800 — intervention group
Group type: COMPARATOR
Intervention: Standard BU-CY conditioning regimen (historical control)
Number of subjects: 33
Study 7868872 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt intake (200 mmol/day)
Number of subjects: 15
Study 7868872 — intervention group
Group type: COMPARATOR
Intervention: Low salt intake (50 mmol/day)
Number of subjects: 15
Study 7868872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium depletion in salt-resistant hypertensives
Number of subjects: 15
Study 7868872 — intervention group
Group type: COMPARATOR
Intervention: Sodium replete state in salt-resistant patients
Number of subjects: 15
Study 7868872 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma calcitonin gene-related peptide with plasma renin activity in salt-resistant patients
Number of subjects: 15
Study 7868872 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in plasma calcitonin gene-related peptide due to salt intake
Number of subjects: 15
Study 7868872 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone levels
Number of subjects: 15
Study 2908008 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 15 mg intravenously
Number of subjects: 8
Study 2908008 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 30 mg intravenously
Number of subjects: 8
Study 2908008 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (both doses)
Number of subjects: 8
Study 31704549 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg twice daily for 52 weeks
Number of subjects: 0
Study 31704549 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 28566525 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (40.2 mg)
Number of subjects: 89
Study 28566525 — intervention group
Group type: EXPERIMENTAL
Intervention: MIX (22.8 mg all-rac-alpha-tocopherol acetate + 20.1 mg RRR-alpha-tocopherol)
Number of subjects: 89
Study 28566525 — intervention group
Group type: EXPERIMENTAL
Intervention: ARAC (45.5 mg all-rac-alpha-tocopherol acetate)
Number of subjects: 89
Study 28566525 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol
Number of subjects: 89
Study 28566525 — intervention group
Group type: COMPARATOR
Intervention: MIX and ARAC
Number of subjects: 89
Study 24750558 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR 300 mg/day
Number of subjects: 0
Study 24750558 — intervention group
Group type: COMPARATOR
Intervention: Tapentadol PR 500 mg/day
Number of subjects: 0
Study 24750558 — intervention group
Group type: COMPARATOR
Intervention: Tapentadol PR 300 mg/day plus pregabalin 300 mg/day
Number of subjects: 0
Study 24006819 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing 3, 5, and 7% cinnamon powder
Number of subjects: 0
Study 24006819 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what diet)
Number of subjects: 0
Study 21633600 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures (Vicryl)
Number of subjects: 125
Study 21633600 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable sutures (Silk)
Number of subjects: 125
Study 19178610 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (Intact pleural cavity)
Number of subjects: 320
Study 19178610 — intervention group
Group type: COMPARATOR
Intervention: Group II (Opened pleural cavity)
Number of subjects: 320
Study 16544235 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient education program (AFAS)
Number of subjects: 120
Study 16544235 — intervention group
Group type: COMPARATOR
Intervention: Sham-training (control group)
Number of subjects: 120
Study 15286116 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11677701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics (trained health visitors)
Number of subjects: 25
Study 11677701 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 25
Study 9562314 — intervention group
Group type: EXPERIMENTAL
Intervention: Collar therapy for 6 weeks
Number of subjects: 20
Study 9562314 — intervention group
Group type: EXPERIMENTAL
Intervention: Collar therapy for 12 weeks
Number of subjects: 20
Study 9562314 — intervention group
Group type: EXPERIMENTAL
Intervention: Collar therapy
Number of subjects: 20
Study 8179463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (CBT) including breathing retraining, muscle relaxation, cognitive reframing, and exposure to interoceptive and agoraphobic stimuli for 12 sessions.
Number of subjects: 0
Study 8179463 — intervention group
Group type: COMPARATOR
Intervention: Nonprescriptive treatment (reflective listening) for 12 sessions.
Number of subjects: 0
Study 2888638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 250 mg hs for four days prior to chloroquine administration
Number of subjects: 10
Study 2888638 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine sulfate (300‐mg base) only
Number of subjects: 10
Study 29630101 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided implantation of 125I seeds in combination with chemotherapy
Number of subjects: 76
Study 29630101 — intervention group
Group type: COMPARATOR
Intervention: Simple chemotherapy
Number of subjects: 76
Study 27158849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for adherence and depression (CBT‐AD)
Number of subjects: 89
Study 27158849 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 89
Study 24047799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarix™ vaccine
Number of subjects: 102074
Study 23538618 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional corneal cross-linking (CXL)
Number of subjects: 35
Study 23538618 — intervention group
Group type: COMPARATOR
Intervention: Transepithelial corneal cross-linking (CXL)
Number of subjects: 35
Study 19861187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized Triviraten vaccine (including Rubini mumps strain)
Number of subjects: 0
Study 19861187 — intervention group
Group type: COMPARATOR
Intervention: Injected MMR II
Number of subjects: 0
Study 19861187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized Edmonston-Zagreb (EZ) measles vaccine
Number of subjects: 0
Study 19861187 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected Moraten measles vaccine (twice the dosage)
Number of subjects: 0